RETRACTED ARTICLE: Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration, invasion and chemoresistance

Zhipeng Jiang, Zehui Hou, Wei Liu, Zhuomin Yu, Zhiqiang Liang, and Shuang Chen

Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, Guangdong, China

ABSTRACT
The dysregulated circular RNAs (circRNAs) are linked to progression and chemoresistance in colorectal cancer (CRC). However, the role of circRNA protein tyrosine kinase 2 (circPTK2) in CRC progression and chemoresistance is uncertain. The circPTK2, microRNA (miR-136-5p, m6A ‘reader’ protein YTH domain family protein 1 (YTHDF1), β-catenin and cyclin D1 abundances were examined via quantitative reverse transcription PCR or Western blotting. The progression was investigated by cell counting kit-8 (CCK-8), colony formation, transwell and xenograft analysis. The resistance to 5-fluorouracil (5-FU) and oxaliplatin was analyzed via detecting cell viability and apoptosis using CCK-8 analysis and flow cytometry. The binding relationship was examined through dual-luciferase reporter, RNA immunoprecipitation and pull-down analysis. In our study, circPTK2 abundance was enhanced in CRC and associated with liver metastasis, clinical stage and chemoresistance. CircPTK2 knockdown restrained cell proliferation, migration, invasion, resistance to 5-FU and oxaliplatin, and the Wnt/β-catenin signaling. MiR-136-5p was bound with circPTK2 and downregulated in CRC. MiR-136-5p knockdown attenuated the influence of circPTK2 silence on CRC progression and chemoresistance. YTHDF1 was targeted via miR-136-5p and upregulated in CRC samples and cells. MiR-136-5p targeted YTHDF1 to restrain CRC progression and chemoresistance. In addition, we confirmed that circPTK2 silence reduced xenograft tumor growth. In conclusion, circPTK2 interference suppressed CRC proliferation, migration, invasion and chemoresistance via regulating miR-136-5p and YTHDF1.

ABBREVIATIONS: circRNAs: circular RNAs; CRC: colorectal cancer; circPTK2: circRNA protein tyrosine kinase 2; miR: microRNA; YTHDF1: YTH domain family protein 1; CCK-8: cell counting kit-8; 5-FU: 5-fluorouracil; RIP: RNA immunoprecipitation.

1. Introduction
Colorectal cancer (CRC) is a type of deadly cancer with about 900,000 deaths each year [1]. The incidence in younger ages (<50 years old) is rising because of the complex risk factors, such as obesity, poor diets, alcohol drinking and smoking [2]. The distant metastasis is one main malignancy of CRC, liver metastasis (LM) occurs in about 15–25% of CRC patients [3]. 5-fluorouracil (5-FU) and oxaliplatin are two common anti-tumor drugs for chemotherapy of CRC. However, the development of resistance can limit the therapeutic effect of drug on CRC. Therefore, it is necessary to find novel targets for CRC treatment and improvement of the chemotherapy efficacy.

Noncoding RNAs are implicated in CRC tumorigenesis, and can act as important targets for CRC treatment [4]. Circular RNAs (circRNAs) are a type of noncoding RNAs without 5’ caps and 3’ polyadenylated tails, which are involved in multiple cancer cell processes in CRC [5]. Moreover, the dysregulated circRNAs are linked to chemoresistance of CRC [6]. Emerging evidence suggests that circRNA/microRNA (miRNA)/mRNA regulatory networks have important functions in CRC development and treatment. For example, circ_0007142 promoted cell proliferation and metastasis by modulating miR-455-5p/SGK1 axis in CRC [7]. Furthermore, circ_0007031 increased 5-FU resistance in CRC by regulating...
miR-133b/ABCC5 axis [8]. Additionally, circ_0079662 contributed to the oxaliplatin resistance of CRC through TNF-α pathway [9]. In the past research, hsa_circ_0003221 (circPTK2) had been found to exhibit an oncogenic role in bladder cancer [10]. More importantly, circPTK2 had been discovered to be dysregulated in CRC [11]. Nevertheless, the function of circPTK2 in CRC progression and chemoresistance is uncertain.

MiRNAs are small noncoding RNA molecules which have key functions in the diagnosis, prognosis and treatment of CRC [12]. Furthermore, miRNAs are associated with the regulation of chemoresistance in CRC, including 5-FU and oxaliplatin [13,14]. MiR-136-5p is an anti-carcinogenic miRNA in CRC by repressing cell growth, metastasis and drug resistance [15,16]. However, whether miR-136-5p is relevant to circPTK2-mediated CRC progression and chemoresistance remains unclear. YTH domain family protein 1 (YTHDF1) is a type of m6A ‘reader’ protein that promotes the translation efficacy of m6A-modified mRNAs via interacting with translation initiation factors, which plays as an oncogene in human cancers [17]. In addition, YTHDF1 was highly expressed in CRC [18], and could promote tumorigenesis and cancer stem cell-like activity [19]. Nevertheless, it is unknown whether YTHDF1 is modulated by circPTK2 in CRC. Bioinformatics analysis predicted that miR-136-5p might interact with circPTK2 and YTHDF1, while their interaction had not been reported in CRC.

The aim of this study was to reveal the role and potential molecular mechanisms of circPTK2 in CRC progression and chemoresistance. Based on our preliminary results, we hypothesized that circPTK2 mediated CRC progression and chemoresistance by regulating the miR-136-5p/YTHDF1 axis. Our study hopes to provide new insights into the pathology of CRC and new potential targets for the treatment of CRC.

2. Materials and methods

2.1 Bioinformatics analysis

The targets of circPTK2 were searched using starBase (http://starbase.sysu.edu.cn/) and circinteractome (http://circinteractome.irp.nia.nih.gov/). The miRNA levels in CRC tissues were predicted via dbDEMC 2.0 database (http://www.picb.ac.cn/dbDEMC/). YTHDF1 abundance in CRC was predicted via UALCAN (http://ualcan.path.uab.edu/index.html). The targeted site of miR-136-5p on YTHDF1 was predicted by starBase.

2.2 Patients and tissues

Fifty-five patients with CRC (18 cases with LM-positive and 37 cases with LM-negative; 31 cases at stage I and II, and 24 cases at stage III; 30 cases with chemoresistance, and 25 cases with chemosensitivity) were enrolled in the Sixth Affiliated Hospital of Sun Yat-sen University. The paired tumor and normal non-tumor tissues were collected during the surgery. No patient received anti-tumor therapy before surgery, and each participant provided the written informed consent. Our work was approved by the ethics committee of the Sixth Affiliated Hospital of Sun Yat-sen University.

2.3 Cell culture

Human CRC cell lines HT-29 (cat# BNCC337731), LoVo (cat# BNCC302153), SW480 (cat# BNCC100604), HCT116 (cat# BNCC100596) and normal colonic epithelial cell line (NCM460, cat# BNCC353657) were obtained from BeNa Culture Collection (Beijing, China), and grown in RPMI-1640 medium (cat# 30118844; Solarbio, Beijing, China) plus 10% FBS (cat# 13011–8611; Zhejiang Tianhang Biotechnology, Huzhou, China) and 1% penicillin/streptomycin (cat# 15070063; Thermo Fisher Scientific, Waltham, MA, USA) at 37°C and 5% CO₂.

2.4 Cell transfection

The overexpression vectors of YTHDF1 (oe-YTHDF1) were constructed via our laboratory, with pcDNA3.1 vector (HonorGene, Changsha, China) as control. Short hairpin RNA (shRNA) for circPTK2 (sh-circPTK2-1/2), miR-136-5p mimic, inhibitor (anti-miR-136-5p), and their negative controls were generated via Genomeditech (Shanghai, China). For cell transfection, Lipofectamine 2000 (Thermo Fisher Scientific) was used. After 24 h, cells were harvested for functional experiments.
2.5 qRT-PCR

RNA was extracted using Trizol (Vazyme, Nanjing, China). Then cDNA was generated from RNA via reverse transcription using M-MLV Reverse Transcriptase kit (Thermo Fisher Scientific). SYBR (Vazyme) was used for qRT-PCR. The specific primer sequences were exhibited in Table 1. Relative RNA level was analyzed via 2⁻ΔΔCt method with U6 or β-actin as a reference according to the previous study [20].

2.6 Cell counting kit-8 (CCK-8) and colony formation analysis

Base on the previous study [20], 1 × 10⁴ HT-29 and LoVo cells were placed in 96-well plates, and incubated for 24, 48 or 72 h. Then 10 μL CCK-8 solution (Beyotime, Shanghai, China) was added to each well for 2 h. The optical density (OD) level at 450 nm was measured through microplate reader.

For colony formation analysis, HT-29 and LoVo cells (300 cells) were added in 6-well plates and incubated for 10 days. Cells were stained using 0.1% crystal violet (Beyotime), and the clones were imaged and counted according to the previous study [20].

2.7 Transwell analysis

The experimental procedure was consistent with previous studies [16]. For invasion analysis, the 24-well transwell chambers (Corning Inc., Corning, NY, USA) were coated with Matrigel (Solarbio), and 5 × 10⁵ cells in RPMI-1640 medium without serum were seeded in the upper chambers. For migration analysis, the chambers were not incubated with the Matrigel, and 1 × 10⁵ cells in RPMI-1640 medium without serum were added in the upper chambers. The lower chambers were filled with serum medium. After 24 h, cells in the lower chambers were stained using 0.1% crystal violet, followed by observation under a 100 × magnification microscope. The number of migratory or invaded cells was determined by Image J v1.5.

2.8 Chemoresistance analysis

According to the previous study [16], HT-29 and LoVo cells were placed in 96-well plates, and exposed to various doses of 5-FU (Aladdin, Shanghai, China) or oxaliplatin (Aladdin) for 24 h. Next, cells were incubated with 10 μL CCK-8 reagent for 3 h, and the OD value at 450 nm was examined using a microplate reader. Relative cell viability was expressed as percentage by normalizing to the non-treated group, and the viability curve was made according to the cell viability at different exposure doses. The half maximal inhibitory concentration (IC50) of 5-FU or oxaliplatin was determined at 50% of cell viability according to the viability curve. In addition, flow cytometry was used to assess cell apoptosis. In brief, transfected HT-29 and LoVo cells were treated with 5-FU (1 μM) or oxaliplatin (0.1 μM) for 24 h. and then the cells were collected and double-stained by Annexin V-FITC and PI solution using Annexin V-FITC Apoptosis Detection Kit (Solarbio). Cell apoptosis was analyzed by flow cytometer.

2.9 Western blotting

According to the previous study [20], protein was extracted via RIPA buffer (Beyotime), and quantified with a BCA kit (Thermo Fisher Scientific) following the instructions. Total of 20 μg samples

| Name          | Forward                     | Reverse                           |
|---------------|-----------------------------|-----------------------------------|
| circP1K2      | GGCAGTCATGCTGGAGATG         | TGTGATTGATGTTGGGTCA               |
| YTHDF1        | ACCCTGCTCGATCCATACCCCG      | TGGTAGGTAATGGAATGGGAG             |
| miR-136-5p    | GCCGAGCTCCATTGTTTGG         | AAGTCAGGGGTCCCGAGGATT            |
| miR-330-3p    | GCCGAGCTCCATTGTTTGG         | AAGTCAGGGGTCCCGAGGATT            |
| miR-582-3p    | GCCGAGCTCCATTGTTTGG         | AAGTCAGGGGTCCCGAGGATT            |
| U6            | ATGGAGACGATACAGAGAGATT      | GGAAGCGTTTCAAGGAGATT             |
| β-actin       | CATGTACCGTGTATCCAGGC        | CTCCCTAAATGTCACGCGAGAT           |

Table 1. The primer sequences for qRT-PCR in this study.
were separated via SDS-PAGE gel, and transferred on PVDF membrane. The membranes were blocked using skimmed milk, and then incubated with primary and secondary antibodies, followed by exposing to enhanced chemiluminescence (Solarbio). The blots were analyzed using Image J v1.8 with β-actin as a normalized reference. The antibodies used in this study were provided by Abcam (Cambridge, MA, USA), including anti-β-catenin (ab32572, 1:3000 dilution), anti-cyclin D1 (ab16663, 1:100 dilution), anti-YTHDF1 catenin (ab32572, 1:3000 dilution), anti-cyclin D1 and anti-IgG (ab97051, 1:5000 dilution) and IgG (ab179467, 1:5000 dilution).

2.10 Dual-luciferase reporter, RNA immunoprecipitation (RIP) and pull-down analysis

According to the previous study [21], the wild-type (wt) luciferase reporter vectors circPTK2-wt and YTHDF1 3’UTR-wt were constructed via inserting the sequence of circPTK2 or YTHDF1 3’UTR containing miR-136-5p binding sites into the pmir-GLO vector. The mutant (mut) circPTK2-mut and YTHDF1 3’UTR-mut were formed via mutating the complementary sites (… AAUGGAG …) of miR-136-5p to (… UUACCUC …). HT-29 and LoVo cells were transfected with the vectors and miR-136-5p mimic or miR-NC. After 24 h, luciferase activity was examined with a Dual-Lucy Assay Kit (Solarbio), and normalized to the luciferase activity of Renilla.

Based on the previous research [22], 1 × 10⁷ HT-29 and LoVo cells were lysed in lysis buffer, and analyzed with a Magna RIP™ RNA-Binding Protein Immunoprecipitation kit (Sigma-Aldrich, St. Louis, MO, USA). In brief, the lysates were interacted with the magnetic beads pre-coated with anti-Ago2 or anti-IgG for 6 h. Then, RNA on the beads were extracted, and used for the detection of circPTK2, miR-136-5p and YTHDF1 levels.

According to the previous study [8], Pierce™ Magnetic RNA-Protein Pull-Down kit (Thermo Fisher Scientific) was used in RNA pull-down analysis. Briefly, the biotin-labeled circPTK2 probe, negative control (oligo probe), biotin-miR-136-5p and biotin-miR-NC were generated and interacted with the streptavidin magnetic beads. Then 1 × 10⁷ HT-29 and LoVo cells were lysed, and interacted with the coated beads for 6 h. Then RNA on the beads was eluted, and miR-136-5p, miR-330-3p, miR-582-3p and YTHDF1 levels were detected by qRT-PCR.

2.11 Xenograft model

Total of 10 male BALB/c nude mice (5-week-old) were obtained from Vital River (Beijing, China). According to the previous study [8], LoVo cells (5 × 10⁶ per mouse) stably transfected with lentivirus-carrying sh-circPTK2-1 or sh-NC were injected in mice by subcutaneous injection (n = 5). Tumor volume was examined every 7 days. After 28 days, mice were euthanized according to the guidelines of inhalation anesthesia using 5% isoflurane (Sigma-Aldrich) and cervical dislocation. No unexpected deaths were involved in this study. The tumors were collected and weighed, and then used for the detection of circPTK2, miR-136-5p, YTHDF1, β-catenin and cyclin D1 levels. In addition, paraffin sections of tumor tissue were prepared and immunohistochemical (IHC) staining was performed. The animal experiments were performed under the approval of the Animal Ethics Committee of the Sixth Affiliated Hospital of Sun Yat-sen University.

2.12 Statistical analysis

Data were displayed as mean ± SD. The difference was analyzed by Student t-test or one-way ANOVA followed via Tukey’s post hoc test using GraphPad Prism 8. The difference was significant when P < 0.05.

3. Results

Here, we aimed to explore the role and mechanism of circPTK2 in regulating CRC progression and chemoresistance. In this research, we proposed the hypothesis of circPTK2/miR-136-5p/YTHDF1 axis. Through functional experiments, we found that circPTK2 promoted CRC progression and chemoresistance via regulating the miR-136-5p/YTHDF1 axis.
3.1 circPTK2 abundance is increased in CRC

To explore whether circPTK2 was involved in CRC progression, circPTK2 level was examined in CRC tissues. Compared with normal samples, circPTK2 abundance was evidently higher in CRC tissues (n = 55) (Figure 1(a)). Moreover, the patients were divided into LM-positive (n = 18) or negative (n = 37) group, and circPTK2 expression was higher in LM-positive patients than LM-negative group (Figure 1(b)). Furthermore, 31 patients were at stage I and II, and 24 patients were at stage III. As displayed in Figure 1(c), circPTK2 abundance was markedly increased in patients at stage III compared with those in stage I and II. Additionally, increased level of circPTK2 was shown in patients with chemo-resistance (n = 30) compared with chemo-sensitive subjects (n = 25) (Figure 1(d)). In addition, circPTK2 expression was detected in CRC cells and NCM460. Results showed that circPTK2 abundance was significantly enhanced in CRC cells in comparison to NCM460 cells (Figure 1(e)). These results suggested the high expression of circPTK2 might be associated with CRC progression. Analysis showed that circPTK2 is located at chr8 and is formed by the back-splicing of the exons 3–7 of PTK2 gene (Figure 1(f)).

3.2 circPTK2 knockdown represses CRC cell progression and chemoresistance

To study the function of circPTK2 on CRC progression and chemoresistance, circPTK2 expression was knocked down in HT-29 and LoVo cells. The transfection of sh-circPTK2-1 and sh-circPTK2-2 effectively decreased circPTK2 abundance in the two cell lines (Figure 2(a)). Furthermore, functional experiments were performed...
conducted to investigate the function of circPTK2 on CRC progression. The data of CCK-8 and colony formation analysis showed circPTK2 knockdown significantly reduced the proliferation of HT-29 and LoVo cells via decreasing cell proliferation and colony-formation ability (Figure 2(b-e)). In addition, transwell analysis showed circPTK2 silence evidently constrained the migratory and invaded abilities (Figure 2(f-i)). Moreover, the influence of circPTK2 silence on chemoresistance was analyzed in HT-29 and LoVo cells after exposure to different doses of 5-FU or oxaliplatin. The viability curves were shown in Figure 2(j-m), and circPTK2 knockdown clearly decreased the IC50 of 5-FU or oxaliplatin. Additionally, the influence of circPTK2 knockdown on the Wnt/β-catenin signaling was investigated in HT-29 and LoVo cells. Results showed that circPTK2 interference markedly inhibited β-catenin and cyclin D1 levels (Figure 2(n,o)). In addition, we found that interference of circPTK2 enhanced the apoptosis of HT-29 and LoVo cells induced by 5-Fu and oxaliplatin (Supplementary Figure 1A-B). These results indicated circPTK2 silence restrained CRC progression and chemoresistance.

**Figure 2.** The function of circPTK2 knockdown on cell proliferation, migration, invasion and chemoresistance in CRC cells. HT-29 and LoVo cells were transfected with sh-NC, sh-circPTK2-1 or sh-circPTK2-2. (a) circPTK2 abundance was determined by qRT-PCR. (b and c) Cell proliferation was detected by CCK-8 assay. (d and e) Colony formation was analyzed by colony formation assay. (f-i) Cell migration and invasion were measured by transwell assay. (j-m) Cell viability was determined by CCK-8 assay. (n and o) β-catenin and cyclin D1 abundances were measured by WB analysis. ***P < 0.001.
3.3 miR-136-5p is targeted by circPTK2

To explore the mechanism addressed via circPTK2 in CRC, the Ago2-RIP assay was conducted in HT-29 and LoVo cells. Results exhibited circPTK2 was enriched via Ago2-coated beads, and the enrichment level of circPTK2 was decreased by transfection of sh-PTK2, suggesting circPTK2 might interact with miRNAs in an Ago2-dependent manner (Figure 3(a, b)). Then the targeted miRNAs of circPTK2 were analyzed via starBase and circinteractome, and there were 6 miRNAs (miR-136-5p, miR-182-5p, miR-330-3p, miR-582-3p, miR-665 and miR-758-3p) that were predicted via the two algorithms (Figure 3(c)). In the 6 miRNAs, miR-136-5p, miR-330-3p and miR-582-3p were predicted to be downregulated in CRC via dbDEMC 2.0 database (Figure 3(d)). Moreover, RNA pull-down assay was performed to explore the binding of circPTK2 and the three miRNAs, which showed miR-136-5p had highest binding ability to circPTK2 than miR-330-3p and miR-582-3p (Figure 3(e,f)). Hence, miR-136-5p was used for subsequent experiments. The target sequence of circPTK2 and miR-136-5p was exhibited in Figure 3(g). Additionally, the target interaction of circPTK2 and miR-136-5p was analyzed via dual-luciferase reporter analysis in HT-29 and LoVo cells transfected with circPTK2-wt or circPTK2-mut and miR-NC or miR-136-5p mimic. The efficacy of miR-136-5p mimic was validated via qRT-PCR (Figure 3(h)). Furthermore, the data of dual-luciferase reporter analysis showed miR-136-5p overexpression evidently decreased the luciferase activity of circPTK2-wt, whereas it did not change the activity of circPTK2-mut (Figure 3(i,j)). In addition, miR-136-5p abundance was measured in CRC tissues and cells. As displayed in Figure 3(k,L), miR-136-5p level was significantly declined in CRC tissues and cell lines (HT-29 and LoVo). These data suggested circPTK2 could target miR-136-5p in CRC.

![Figure 3. The interaction relationship of circPTK2 and miR-136-5p. (a and b) circPTK2 enrichment level was detected after Ago2 or IgG RIP assay in HT-29 and LoVo cells. (c) The targeted miRNAs of circPTK2 were predicted and analyzed via starBase and circinteractome. (d) The targeted miRNA levels in CRC were predicted via dbDEMC 2.0. (e and f) miRNA levels were measured after RNA pull-down analysis. (g) The binding site of circPTK2 and miR-136-5p. (h) miR-136-5p level was determined in HT-29 and LoVo cells with transfection of miR-NC or miR-136-5p mimic. (i and j) Luciferase activity was measured in HT-29 and LoVo cells with transfection of circPTK2-wt or circPTK2-mut and miR-NC or miR-136-5p mimic. (k) miR-136-5p expression was measured in CRC and normal samples. (l) miR-136-5p abundance was examined in HT-29, LoVo and NCM460 cells. *P < 0.05, **P < 0.01, ***P < 0.001.](https://example.com/finalized-figure3.png)
3.4 miR-136-5p knockdown attenuates the influence of silence of circPTK2-mediated CRC progression and chemoresistance

To analyze whether miR-136-5p was required for circPTK2-modulated CRC progression and chemoresistance, HT-29 and LoVo cells were transfected with sh-circPTK2-1 and anti-miR-136-5p. The knockdown efficacy of anti-miR-136-5p on miR-136-5p was validated in Figure 4(a). Moreover, miR-136-5p knockdown mitigated the suppressive effect of circPTK2 silence on proliferation and colony-formation ability of HT-29 and LoVo cells (Figure 4(b-e)). Additionally, miR-136-5p downregulation attenuated knockdown of circPTK2-mediated suppression of cell migration and invasion (Figure 4(f-i)). Furthermore, miR-136-5p knockdown abolished the inhibitory effect of circPTK2 knockdown on the IC50 of 5-FU or oxaliplatin (Figure 4(j-m)). Also, the promotion effect of si-circPTK2 on the apoptosis of 5-FU or oxaliplatin-induced CRC cells also were reversed by miR-136-5p inhibitor (Supplementary Figure 1c-d). In addition, miR-136-5p knockdown rescued β-catenin and cyclin D1 levels from circPTK2 silence (Figure 4(n, o)). These results showed circPTK2 silence suppressed CRC progression and chemoresistance via regulating miR-136-5p.

3.5 YTHDF1 is targeted miR-136-5p

To further explore the mechanism addressed via circPTK2/miR-136-5p axis in CRC, the targets of miR-136-5p were searched via starBase. The increased abundance of YTHDF1 in colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) was predicted via UALCAN (Figure 5(a,b)). Moreover, YTHDF1 was a candidate target for miR-136-5p, and the binding site of miR-136-5p and YTHDF1 was displayed in Figure 5(c). In addition, the dual-luciferase reporter, RIP assay and RNA pull-down analysis were conducted to validate the association of miR-136-5p and YTHDF1. MiR-136-5p overexpression markedly caused the reduction of luciferase activity of YTHDF1 3’ UTR-wt, while it showed little effect on the activity of YTHDF1 3’ UTR-mut (Figure 5(d, e)). Furthermore, Ago2 RIP and RNA pull-down assays showed YTHDF1 could bind to miR-136-5p (Figure 5(f-h)). Then the influence of miR-136-5p on YTHDF1 abundance was evaluated in HT-29 and LoVo cells. Results showed YTHDF1 protein abundance was negative regulated via miR-136-5p (Figure 5(i,j)). Additionally, YTHDF1 expression was examined in CRC tissues and cells. As shown in Figure 5(k-n), YTHDF1 abundance was significantly elevated in CRC tissue samples and cells. These results suggested YTHDF1 was targeted via miR-136-5p in CRC.

3.6 miR-136-5p overexpression suppresses CRC cell progression and chemoresistance by decreasing YTHDF1

To study the function of miR-136-5p/YTHDF1 axis in CRC progression and chemoresistance, HT-29 and LoVo cells were transfected with miR-136-5p mimic and oe-YTHDF1. The overexpression efficacy of oe-YTHDF1 on YTHDF1 was identified in Figure 6(a). Furthermore, miR-136-5p overexpression evidently decreased cell proliferation and colony-formation ability, and these events were attenuated via YTHDF1 upregulation (Figure 6(b-e)). Additionally, miR-136-5p overexpression markedly repressed cell migration and invasion, which were abolished via YTHDF1 restoration (Figure 6(f-i)). Moreover, miR-136-5p addition remarkably reduced the IC50 of 5-FU or oxaliplatin, which was rescued by YTHDF1 overexpression (Figure 6(j-m)). Moreover, miR-136-5p promoted the apoptosis of 5-FU or oxaliplatin-induced CRC cells, and this effect also was overturned by YTHDF1 overexpression (Supplementary Figure 1(e-f)). In addition, miR-136-5p evidently repressed the Wnt/β-catenin pathway via decreasing β-catenin and cyclin D1 abundances, and these events were abrogated by YTHDF1 overexpression (Figure 6(n,o)). These results indicated miR-136-5p targeted YTHDF1 to repress CRC progression and chemoresistance.

3.7 circPTK2 modulates YTHDF1 expression via miR-136-5p

To analyze how and whether circPTK2 could modulate YTHDF1 in CRC, HT-29 and LoVo cells were transfected with sh-NC + anti-miR-NC, sh-circPTK2-1 + anti-miR-NC or sh-circPTK2-1 + anti-miR-136-5p. Results showed YTHDF1 protein abundance was
significantly reduced via circPTK2 silence, and this effect was attenuated via miR-136-5p knockdown (Figure 7(a,b)). These results suggested circPTK2 could modulate YTHDF1 via regulating miR-136-5p.

3.8 circPTK2 silence decreases tumor growth

To study the function of circPTK2 on CRC progression in vivo, LoVo cells stably transfected with sh-NC or sh-circPTK2-1 were used to establish the xenograft model, and the mice were divided into sh-NC or sh-circPTK2-1 group (n = 5). At the ending, tumor volume and weight were clearly lower in sh-circPTK2-1 group than sh-NC group (Figure 8(a-c)). Furthermore, we confirmed that circPTK2 expression was reduced, while miR-136-5p expression was elevated the tumors of sh-circPTK2-1 group (Figure 8(d)). IHC staining results showed that
YTHDF1 and Ki-67 positive cells were reduced in the tumors of sh-circPTK2-1 group (Figure 8(e)). As shown in Figure 8(f), YTHDF1, β-catenin and cyclin D1 abundances were evidently decreased in sh-circPTK2-1 group. These data showed circPTK2 knockdown decreased CRC cell growth in a xenograft model.

### 4. Discussion

CRC is a frequent tumor malignancy with high incidence and mortality worldwide [23]. The outcomes of CRC patients at advanced stage are poor, thus new strategies are needed for the treatment of CRC [23]. CircRNAs are potential therapeutic targets for cancer, which are relevant to CRC progression and chemoresistance [6,24]. Here we investigated the anti-tumor function of circPTK2 silence in CRC by repressing cancer progression and chemoresistance. Furthermore, we were the first time to validate the importance of circPTK2/miR-136-5p/YTHDF1 network in regulating CRC development.

Previous studies reported circPTK2 (hsa_circ_0003221) played an oncogenic role in cancers, including bladder cancer and gastric cancer...
Chen et al. found circPTK2 (hsa_circ_0003221) was dysregulated in CRC [11], while they did not study the function of this circRNA. Here we measured the function of circPTK2 in CRC, and found circPTK2 (hsa_circ_0003221) knockdown constrained cancer progression and chemoresistance. These data indicated the anti-cancer potential of circPTK2 (hsa_circ_0003221) knockdown in CRC, which was also similar to another type of circPTK2 (hsa_circ_0005273) [26]. Furthermore, the Wnt/β-catenin signaling is associated with CRC development [27]. The former reports have indicated this signaling pathway contributed to CRC growth, metastasis and chemoresistance to 5-FU and oxaliplatin [28–30]. Hence, we further explored and found circPTK2 knockdown blocked the Wnt/β-catenin pathway. These all suggested circPTK2 might function as a potential target for CRC treatment.

A circRNA/miRNA/mRNA network was established to underlie the mechanism of circRNA in CRC [31]. After analyzing the targets of circPTK2, our study firstly validated the influence of miR-136-5p and YTHDF1 on CRC progression and chemoresistance. (a) YTHDF1 protein level was examined in HT-29 and LoVo cells transfected with vector or oe-YTHDF1. (b-o) HT-29 and LoVo cells were transfected with miR-136-5p mimic and oe-YTHDF1. Cell proliferation (b and c), colony formation (d and e), migration (f and g), invasion (h and i), 5-FU resistance (j and k), oxaliplatin resistance (l and m), β-catenin and cyclin D1 protein expression (n and o) were examined by CCK-8 assay, colony formation assay, transwell assay and WB analysis. *P < 0.05, **P < 0.01, ***P < 0.001.
miR-136-5p was targeted by circPTK2. Jin et al. reported miR-136-5p could repress CRC cell proliferation, migration and invasion by targeting src homology 2B adaptor protein 1 (SH2B1) [32]. Moreover, Gao et al. suggested miR-136-5p repressed CRC cell migration, invasion and oxaliplatin resistance by modulating E2F transcription factor 1 (E2F1) [16]. Wnt/β-catenin pathway was inactivated via miR-136-5p in breast cancer and CRC [15,33]. These reports indicated the anti-tumor role of miR-136-5p in CRC. Similarly, we also validated this function, and found that circPTK2 modulated CRC progression and chemoresistance by regulating miR-136-5p.

Next, we confirmed YTHDF1 was targeted via miR-136-5p. Previous evidences suggested YTHDF1 predicted the poor prognosis and played an oncogenic role by promoting malignant processes and chemoresistance in cancers, like breast cancer and ovarian cancer [34,35]. YTHDF1 could serve as an important prognostic factor for CRC [36]. Moreover, YTHDF1 could promote tumorigenesis of CRC by activating the Wnt/β-catenin pathway [19], and it might be upregulated by c-Myc [37]. A recent study suggested that YTHDF1 promoted of GLS1 protein synthesis to enhance the cisplatin resistance of CRC [38]. Importantly, high YTHDF1 expression had been found to be related to the poor prognosis of
COAD patients, and it might be a promising biomarker for COAD [39]. These reports indicated the carcinogenic role of YTHDF1 in CRC. Similarly, we also found this function, and validated the anti-cancer role of miR-136-5p was associated with YTHDF1. Additionally, we found circPTK2 modulated YTHDF1 abundance via competitively binding to miR-136-5p. In this way, circPTK2 regulated CRC progression and chemoresistance. Furthermore, the anti-tumor effect of circPTK2 silence was also validated with a xenograft model.

5. Conclusion

In conclusion, this study on the function of circPTK2 in CRC showed circPTK2 knockdown suppressed CRC progression and chemoresistance, possibly by regulating the miR-136-5p/YTHDF1 axis. Our study explores a novel mechanism for understanding the pathogenesis of CRC, and provides a new target for CRC treatment.

Highlights

1. Knockdown of circPTK2 inhibits CRC progression and chemoresistance.
2. MiR-136-5p can be sponged by circPTK2.
3. YTHDF1 is targeted by miR-136-5p.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Authors’ contributions

Zh H and WL designed and performed the research; Zm Y, Zq L and SC analyzed the data; Zp J wrote the manuscript. All authors read and approved the final manuscript. Written informed consents were obtained from all participants and this study was permitted by the Ethics Committee of The Sixth Affiliated Hospital of Sun Yat-sen University, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Supported by National Key Clinical Discipline, Guangzhou 510655, Guangdong, P.R.China.

Ethics approval and consent to participate

The research has been carried out in accordance with the World Medical Association Declaration of Helsinki, and that all subjects provided written informed consent.

Animal studies were performed in compliance with the ARRIVE guidelines and the Basel Declaration. All animals received humane care according to the National Institutes of Health (USA) guidelines.

References

[1] Dekker E, Tanis PJ, Vlugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467–1480.
[2] Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16 (12):713–732.
[3] Kow AWC. Hepatic metastasis from colorectal cancer. J Gastrointest Oncol. 2019;10(6):1274–1298.
[4] Esmaeili M, Keshani M, Vakilian M, et al. Role of non-coding RNAs as novel biomarkers for detection of colorectal cancer progression through interaction with the cell signaling pathways. Gene. 2020;753:144796.
[5] Hao S, Cong L, Qu R, et al. Emerging roles of circular RNAs in colorectal cancer. Onco Targets Ther. 2019;10:4765–4777.
[6] Abu N, Hon KW, Jeyaraman S, et al. Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics. 2019;11(8):875–884.
[7] Wen T, Wu H, Zhang L, et al. Circular RNA circ_0007142 regulates cell proliferation, apoptosis, migration and invasion via miR-455-5p/SNK1 axis in colorectal cancer. Anticancer Drugs. 2021;32(1):22–33.
[8] He X, Ma J, Zhang M, et al. Circ_0007031 enhances tumor progression and promotes 5-fluorouracil resistance in colorectal cancer through regulating miR-133b/ABCC5 axis. Cancer Biomark. 2020;29 (4):531–542.
[9] Lai M, Liu G, Li R, et al. Hsa_circ_0079662 induces the resistance mechanism of the chemotherapy drug oxaliplatin through the TNF-alpha pathway in human colon cancer. J Cell Mol Med. 2020;24(9):5021–5027.
[10] Xu ZQ, Yang M-G, Liu H-J, et al. Circular RNA hsa_circ_003221 (circPTK2) promotes the proliferation and migration of bladder cancer cells. J Cell Biochem. 2018;119(4):3317–3325.
[11] Chen RX, Chen X, Xia L-P, et al. N(6)-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat Commun. 2019;10(1):4695.
[12] Sur DG, Colceriu M, Sur G, et al. MiRNAs roles in the diagnosis, prognosis and treatment of colorectal cancer. Expert Rev Proteomics. 2019;16(10):851–856.

[13] Blondy S, David V, Verdier M, et al. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111(9):3142–3154.

[14] Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. MicroRNAs in cancer therapy: their involvement in oxaliplatin sensitivity/resistance of cancer cells with a focus on colorectal cancer. Life Sci. 2020;256:117973.

[15] Yuan Q, Cao G, Li J, et al. MicroRNA-136 inhibits colon cancer cell proliferation and invasion through targeting liver receptor homolog-1/Wnt signaling. Gene. 2017;628:48–55.

[16] Gao H, Song X, Kang T, et al. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Oncotarget. 2017;10:205–216.

[17] Liu S, Li G, Li Q, et al. The roles and mechanisms of YTH domain-containing proteins in cancer development and progression. Am J Cancer Res. 2020;10(4):1068–1084.

[18] Liu X, Liu L, Dong Z, et al. Expression patterns and prognostic value of m(6)A-related genes in colorectal cancer. Am J Transl Res. 2019;11(7):3972–3991.

[19] Bai Y, Yang C, Wu R, et al. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. Front Oncol. 2019;9:332.

[20] Yin D, Lu X. Silencing of long non-coding RNA HCP5 inhibits proliferation, invasion, migration, and promotes apoptosis via regulation of miR-299-3p/SMD5 axis in gastric cancer cells. Bioengineered. 2021;12(1):225–239.

[21] Liu Y, Zhang H, Wang H, et al. Long non-coding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR-223-3p mediated regulation of CXCR4. Bioengineered. 2021;12(1):496–506.

[22] Huang Y, Yan Q, Yu D, et al. Long intergenic non-protein coding RNA 960 regulates cancer cell viability, migration and invasion through modulating miR-146a-5p/interleukin 1 receptor associated kinase 1 axis in pancreatic ductal adenocarcinoma. Bioengineered. 2021;12(1):369–381.

[23] Jung G, Hernández-Illán E, Moreira L, et al. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17(2):111–130.

[24] Artemaki PI, Scorilas A, Kontos CK. Circular RNAs: a new piece in the colorectal cancer Puzzle. Cancers (Basel). 2020;12:9.

[25] Yu D, Zhang C. Circular RNA PTK2 accelerates cell proliferation and inhibits cell apoptosis in gastric carcinoma via miR-139-3p. Dig Dis Sci. 2020;66(5):1499–1509.

[26] Yang H, Li X, Meng Q, et al. CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer. Mol Cancer. 2020;19(1):13.

[27] Cheng X, Xu X, Chen D, et al. Therapeutic potential of targeting the Wnt/beta-catenin signaling pathway in colorectal cancer. Biomed Pharmacother. 2019;110:473–481.

[28] Yuan X, Sun X, Shi X, et al. USP39 promotes colorectal cancer growth and metastasis through the Wnt/beta-catenin pathway. Oncol Rep. 2017;37(4):2398–2404.

[29] Jiang J, Chang W, Fu Y, et al. SAV1 represses the development of human colorectal cancer by regulating the Akt-mTOR pathway in a YAP-dependent manner. Cell Prolif. 2017;50(4):3.

[30] Tong C, Qu K, Wang G, et al. Knockdown of DNA binding protein A (dbpA) enhances the chemotherapy sensitivity of colorectal cancer via suppressing the Wnt/beta-catenin/Chk1 pathway. Cell Biol Int. 2020;44(10):2075–2085.

[31] Que F, Wang H, Luo Y, et al. Comprehensive analysis of differentially expressed circRNAs reveals a colorectal cancer-related ceRNA network. Comput Math Methods Med. 2020;2020:7159340.

[32] Jin C, Wang A, Liu L, et al. Hsa_circ_0136666 promotes the proliferation and invasion of colorectal cancer through miR-136/SH2B1 axis. J Cell Physiol. 2019;234(5):7247–7256.

[33] Huan J, Xing L, Lin Q, et al. Long noncoding RNA CRNDE activates Wnt/beta-catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer. Am J Transl Res. 2017;9(4):1977–1989.

[34] Anita R, Paramasivam A, Priyadharsini JV, et al. The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. Am J Cancer Res. 2020;10(8):2546–2554.

[35] Hao L, Wang J-M, Liu B-Q, et al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim Biophys Acta Mol Cell Res. 2019;1888(1):118878.

[36] Liu T, Li C, Jin L, et al. The prognostic value of m6A RNA methylation regulators in colon adenocarcinoma. Med Sci Monit. 2019;25:9435–9445.

[37] Nishizawa Y, Konno M, Asai A, et al. Oncogene c-Myc promotes epitranscriptome m(6)A reader YTHDF1 expression in colorectal cancer. Oncotarget. 2018;9(7):7476–7486.

[38] Chen P, Liu X-Q, Lin X, et al. Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism. Mol Ther Oncolytics. 2021;20:228–239.

[39] Xu D, Shao J, Song H, et al. The YTH Domain Family of N6-Methyladenosine "Readers" in the Diagnosis and Prognosis of Colonic Adenocarcinoma. Biomed Res Int. 2020;2020:9502560.